Bone marrow fibrosis may be an effective independent predictor of the ‘TKI drug response level’ in chronic myeloid leukemia

References

• Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–84.
   PubMed Web of Science ®Google Scholar
• Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opin Pharmacother. 2013;14:2005–10.
   PubMed Web of Science ®Google Scholar
• Sayinalp N, Cinar H, Uner A, Haznedaroglu IC, Buyukasik Y, Goker H, et al. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders. Clin Lab Haematol. 2004;26:265–8.
   PubMedGoogle Scholar
• Cobankara V, Oran B, Ozatli D, Haznedaroglu IC, Kosar A, Buyukasik Y, et al. Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis. Clin Appl Thromb Hemost. 2001;7:126–30.
   PubMed Web of Science ®Google Scholar
• Bennour A, Tabka I, Ben Youssef Y, Kmeria Z, Khelif A, Saad A, et al. A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy. Cancer Biol Med. 2013;10:47–51.
   PubMedGoogle Scholar
• Karimata K, Masuko M, Ushiki T, Kozaki T, Shibasaki Y, Yano T, et al. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Intern Med. 2011;50:481–5.
   PubMed Web of Science ®Google Scholar
• Navarro JT, Feliu E, Grau J, Espiret B, Colomer D, Ribera JM, et al. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol. 2007;82:849–51.
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Sauta MG, Altavilla G. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res. 2009;33:e143–4.
   PubMedGoogle Scholar
• Uz B, Tatonyan SC, Sayitoglu M, Erbilgin Y, Ng OH, Buyukasik Y, et al. Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders. J Renin Angiotensin Aldosterone Syst. 2013;14:308–14.
   PubMed Web of Science ®Google Scholar
• Uz B, Buyukasik Y, Atay H, Kelkitli E, Turgut M, Bektas O, et al. EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology 2013;18:247–52.
   PubMed Web of Science ®Google Scholar
• Lugli A, Ebnoether M, Cogliatti SB, Gratwohl A, Passweg J, Hess U, et al. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Hum Pathol. 2005;36:91–100.
   PubMed Web of Science ®Google Scholar
• Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Höfler G, Haas OA, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381–3.
   PubMed Web of Science ®Google Scholar
• Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, et al. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. Leukemia 2004;18:1460–67.
   PubMed Web of Science ®Google Scholar
• Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007;21:2420–27.
   PubMed Web of Science ®Google Scholar
• Buesche G, Georgii A, Duensing A, Schmeil A, Schlue J, Kreipe HH. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol. 2003;34:391–401.
   PubMed Web of Science ®Google Scholar
• Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial. Leukemia 2003;17:2444–53.
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101:332–6.
   PubMed Web of Science ®Google Scholar
• de Jesus CR, I-Ching L, Carvalho Neiva TdJ, Vituri CdL. Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response. Braz J Pharm Sci. 2011;47:313–22.
   Web of Science ®Google Scholar
• Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, et al. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Am J Clin Pathol. 2003;119:833–41.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderi S, et al. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 2005;104:777–80.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, et al. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 2005;46:993–7.
   PubMed Web of Science ®Google Scholar
• Khonglah Y, Basu D, Dutta TK. Bone marrow trephine biopsy findings in chronic myeloid leukemia. Malays J Pathol. 2002;24:37–43.
   PubMedGoogle Scholar
• Ahmed A, Powers MP, Youker KA, Rice L, Ewton A, Dunphy CH, et al. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study. Pathol Res Pract. 2009;205:634–8.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009;28:1285–97.
   PubMed Web of Science ®Google Scholar
• Mahadevan KK, Basu D, Kumar S. Does CD34 staining reflect the angiogenic process in the bone marrow? An analysis of a series of chronic myeloid Leukemia patients. J Clin Diagn Res. 2014;8:FC04–7.
   PubMedGoogle Scholar
• Rao S, Sen R, Singh S, Ghalaut PS, Arora BB. Grading of marrow fibrosis in chronic myeloid leukemia – a comprehensive approach. Indian J Pathol Microbiol. 2005;48:341–4.
   PubMedGoogle Scholar
• Shirai K, Sera Y, Bulkeley W, Mehrotra M, Moussa O, LaRue AC, et al. Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. 2009;37:1464–71.
   PubMed Web of Science ®Google Scholar
• Srinivas BH, Paul TR, Uppin SG, Uppin MS, Jacob RT, Raghunadharao D. Morphologic changes in the bone marrow in patients of chronic myeloid leukemia (CML) treated with imatinibmesylate. Indian J Hematol Blood Transfus. 2012;28:162–9.
   PubMed Web of Science ®Google Scholar
• Valent P, Agis H, Sperr W, Sillaber C, Horny HP. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leuk lymphoma 2008;49:635–8.
   PubMed Web of Science ®Google Scholar